Optimizing platelet GPVI inhibition versus hemostatic impairment by ibrutinib and the novel Btk-inhibitors acalabrutinib, ONO/GS-4059, BGB-3111 and evobrutinib - Denzinger, V; Busygina, K; Jamasbi, J (Thromb Haemost, 2019)
, et al.